Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease
- PMID: 17520250
- DOI: 10.1007/s00259-007-0454-x
Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease
Abstract
Purpose: Although( 18)F-fluorodeoxyglucose (FDG) PET is an established imaging technique to assess brain glucose utilisation, accurate measurement of tracer concentration is confounded by the presence of partial volume effect (PVE) due to the limited spatial resolution of PET, which is particularly true in atrophic brains such as those encountered in patients with Alzheimer's disease (AD). Our aim was to investigate the effects of PVE correction on FDG PET in conjunction with voxel-based morphometry (VBM) in patients with mild AD.
Methods: Thirty-nine AD patients and 73 controls underwent FDG PET and MRI. The PVE-corrected grey matter PET images were obtained using an MRI-based three-compartment method. Additionally, the results of PET were compared with grey matter loss detected by VBM.
Results: Before PVE correction, reduced FDG uptake was observed in posterior cingulate gyri (PCG) and parieto-temporal lobes (PTL) in AD patients, which persisted after PVE correction. Notably, PVE correction revealed relatively preserved FDG uptake in hippocampal areas, despite the grey matter loss in medial temporal lobe (MTL) revealed by VBM.
Conclusion: FDG uptake in PCG and PTL is reduced in AD regardless of whether or not PVE correction is applied, supporting the notion that the reduced FDG uptake in these areas is not the result of atrophy. Furthermore, FDG uptake by grey matter tissue in the MTL, including hippocampal areas, is relatively preserved, suggesting that compensatory mechanisms may play a role in patients with mild AD.
Comment in
-
'Intensity diffusion' is a better description than 'partial volume effect'.Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):536-7. doi: 10.1007/s00259-008-1032-6. Epub 2009 Jan 21. Eur J Nucl Med Mol Imaging. 2009. PMID: 19156412 No abstract available.
Similar articles
-
Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease.Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):801-9. doi: 10.1007/s00259-005-0050-x. Epub 2006 Mar 21. Eur J Nucl Med Mol Imaging. 2006. PMID: 16550383
-
Comparison of gray matter and metabolic reduction in mild Alzheimer's disease using FDG-PET and voxel-based morphometric MR studies.Eur J Nucl Med Mol Imaging. 2005 Aug;32(8):959-63. doi: 10.1007/s00259-004-1740-5. Epub 2005 Mar 31. Eur J Nucl Med Mol Imaging. 2005. PMID: 15800784 Clinical Trial.
-
Brain FDG PET study of normal aging in Japanese: effect of atrophy correction.Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):794-805. doi: 10.1007/s00259-005-1767-2. Epub 2005 Mar 10. Eur J Nucl Med Mol Imaging. 2005. PMID: 15759148
-
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):486-510. doi: 10.1007/s00259-005-1762-7. Eur J Nucl Med Mol Imaging. 2005. PMID: 15747152 Review.
-
Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease.Neuroimage. 2021 Sep;238:118248. doi: 10.1016/j.neuroimage.2021.118248. Epub 2021 Jun 11. Neuroimage. 2021. PMID: 34119639 Free PMC article. Review.
Cited by
-
Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease.Brain Imaging Behav. 2012 Dec;6(4):568-83. doi: 10.1007/s11682-012-9208-x. Brain Imaging Behav. 2012. PMID: 23179062 Free PMC article.
-
Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease.Cold Spring Harb Perspect Med. 2012 Oct 1;2(10):a011452. doi: 10.1101/cshperspect.a011452. Cold Spring Harb Perspect Med. 2012. PMID: 23028132 Free PMC article. Review.
-
Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data.Neuroimage. 2014 May 15;92:225-36. doi: 10.1016/j.neuroimage.2013.12.021. Epub 2013 Dec 19. Neuroimage. 2014. PMID: 24361666 Free PMC article.
-
Reassessment of Pioglitazone for Alzheimer's Disease.Front Neurosci. 2021 Jun 16;15:666958. doi: 10.3389/fnins.2021.666958. eCollection 2021. Front Neurosci. 2021. PMID: 34220427 Free PMC article. Review.
-
Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment.Sci Rep. 2017 Dec 13;7(1):17490. doi: 10.1038/s41598-017-17718-y. Sci Rep. 2017. PMID: 29235507 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical